Special Report

Published in:
Volume 9 / Year 2020 / Issue 2

Biosimilars markets: US and EU compared

Page: 90-2

Abstract: Differences between the US and European regulatory processes can lead to differences in the time taken for biosimilar approval. The European Medicines Agency is in some cases quicker to… Read More »

Clinical trials for trastuzumab biosimilars

Page: 84-9

Abstract: Clinical trials must demonstrate biosimilarity for regulatory marketing approval to be granted. The GaBI Journal has conducted a search for clinical trials that have been, or are being, carried… Read More »

Go Back Print